Tri-Luma Cream Before and After: Clinical Results on Stubborn Melasma

An insightful review of Tri-Luma Cream Before and After: Clinical Results on Stubborn Melasma—check out what experts are saying.

Monotherapy often disappoints in hyperpigmentation treatment. Hydroquinone alone inhibits tyrosinase, the rate-limiting enzyme responsible for turning tyrosine into melanin. However, thick epidermal barriers and local inflammation frequently blunt its effectiveness. Tri-Luma overcomes these biological hurdles by combining three distinct active agents into a single vehicle:

First, hydroquinone 4 percent halts the production of new melanin inside active melanosomes. Second, tretinoin cream (0.05%) accelerates keratinocyte turnover, purging existing melanin granules from the skin's surface while enhancing the penetration depth of hydroquinone. Third, fluocinolone acetonide (0.01%), a low-potency fluorinated corticosteroid, calms the cellular inflammation caused by tretinoin and hydroquinone, while simultaneously suppressing melanocyte-stimulating hormone.

This tripartite synergy explains why the drug works quickly. Tretinoin stimulates epidermal exfoliation, hydroquinone shuts down the pigment factories beneath, and the steroid controls collateral tissue irritation. Without the corticosteroid, retinoid-induced dermatitis frequently triggers post-inflammatory rebound pigment, particularly in Fitzpatrick skin types III through VI.